行情

IDXG

IDXG

Interpace Biosciences
NASDAQ

实时行情|Nasdaq Last Sale

5.09
+0.07
+1.39%
交易中 09:38 04/02 EDT
开盘
5.09
昨收
5.02
最高
5.09
最低
5.09
成交量
7
成交额
--
52周最高
11.00
52周最低
3.810
市值
1,944.18万
市盈率(TTM)
-0.0846
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测IDXG价格均价为20.80,最高价位31.00,最低价为15.00。

EPS

IDXG 新闻

更多
  • 瑞幸咖啡报告财报审计问题:伪造交易价值约22亿元
  • 新浪科技 · 47分钟前
  • 湖北农产品,淘宝销量翻倍
  • 新浪财经 · 49分钟前
  • 瑞幸咖啡盘前跌72% 调查称伪造交易价值大约22亿元
  • 新浪财经 · 56分钟前
  • 波音向员工提出自愿离职买断计划
  • 新浪财经 · 1小时前

所属板块

管理型医疗保健
-1.73%
医疗保健提供商与服务
-1.79%

热门股票

代码
价格
涨跌幅

IDXG 简况

Interpace Biosciences, Inc., formerly Interpace Diagnostics Group, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, it provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
展开

微牛提供Interpace Biosciences Inc(NASDAQ-IDXG)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的IDXG股票新闻,以帮助您做出投资决策。